CompletedNot applicableNCT01476592

A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors

Studying Neuroendocrine tumor of stomach

Last synced from ClinicalTrials.gov May 14, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Wisconsin, Madison
Principal Investigator: Emily R. Winslow, MD, DDS
University of Wisconsin, Madison
Intervention: Resveratrol(dietary_supplement)
Enrollment: 7 enrolled
Eligibility: 18 years · All sexes
Timeline: 2011 – 2018

Study locations (1)

University of Wisconsin, Madison, Wisconsin, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01476592 on ClinicalTrials.gov

Other trials for Neuroendocrine tumor of stomach

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT00569127
Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor
National Cancer Institute (NCI)

See all trials for Neuroendocrine tumor of stomach →

← Back to all trials